Cite
HARVARD Citation
Herrera, A. et al. (2023). Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet. 10 (1), pp. e14-e23. [Online].